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Localization of a Radiolabeled Monoclonal Antibody to Calcitonin in
Rat Medullary Thyroid Carcinoma Allografts
Naguib A. Samaan,* and Kuo-Pao Yang

A radiolabeled anticalcitonin monoclonal antibody (MoAb) was testedfor tumor-localizing capability
in WAG/Rij rats allografted with cultured medullary thyroid carcinoma cells (line 44-2). '^'I-labeled
anticalcitonin IgG was taken up by the tumors in a time-dependent and dose-dependent manner.
Tumor tissue uptake of the injected MoAb was 0.7 to 1.3%/g of tumor tissue when tested with a dose
range of 40 lo 250 \x.g/kg of body weight. Distribution ratios of the radiolabeled MoAb were 1.2:1 for
tumor-to-blood and 2-20:1 for tumor-to-organs. In rats injected with control IgG, disiribution ratios
of radioactivity were 0.4:1 for tumor-to-blood, and 0.6-2:1 for tumor-to-organs. These results
suggested a specific uptake of MoAb by the tumor Some nonspecific uptake was seen by the visceral
organs. This may represent the metabolic clearance of MoAb. presence of cross-reacting antigens, or
meta.stasis of tumor to these organs. (Henry Ford Hosp Med J 1987:35:153-6)

A

ntibodies against tumor markers are potentially powerful
tools for detecting metastatic malignancies, particularly
small metastatic tumors for which methods of detection are still
lacking. Antibodies against tumor cell-surface antigens or secretory products have been shown to localize in various types of
human neoplasms, both in animals (1-7) and man (8-12). For
medullary thyroid carcinoma (MTC), however, immunolocalization of antibodies against tumor markers of this type has
rarely been demonstrated. Using polyclonal antibodies against
human synthetic calcitonin (CT), Gautvik et al (13) reported a
preferential uptake and localization of the "'1-labeled immunoglobulins in rat MTC tissues. In contrast, Guilloteau et al (14)
found that radiolabeled anti-CT immunoglobulin fragments prepared from ewes' antisera were unsuitable for MTC scintigraphic imaging. In theory, a monoclonal antibody (MoAb)
has the advantage of greater specificity, but its restricted epitope
specificity could have the disadvantage of limiting localizing
efficacy. The suitability of monoclonal anti-CT antibodies for
detecting MTC needs to be tested. We report here our radiotargeting studies in WAG/Rij rats allografted with rat MTC
using i^'I- or '"1-labeled MoAb to CT.

Materials and Methods
Antibody preparations and '-''I- or '^I-labeled antibodies
MoAb to CT (produced by Hybritec, San Diego, CA) was
purchased from Boehringer Mannheim Biochemicals (Indianapolis, IN). Mouse IgG was obtained from Sigma Co (St
Louis, MO). The MoAb and mouse IgG were labeled with '^'I or
'-^1 using a modification ofthe chloramine-T method (15) of
Cambridge Medical Diagnostics (Cambridge, MA). The
labeled MoAb or mouse IgG has a specific activity of 12 to
16 |xCi/p.g.
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Rat MTC
MTC allografts were produced in WAG/Rij rats by subcutaneous injection of cells of an established rat MTC line, 44-2
(rMCT 44-2) (16). These cells were generously provided by Dr.
Robert F. Gagel, Veterans Administration Medical Center, Baylor College of Medicine, Houston, Texas, and were maintained
in our laboratory as monolayer cultures. Flasks of rMTC 44-2
cells were washed with sterile saline and the cells were scraped
off the flasks with a mbber policeman. The cells (about 5 x 10*)
were resuspended in 1 mL of saline and injected into the back of
the rats' necks. Tumors about 1 cm in diameter usually formed in
three to four weeks.
Measurement of serum immunoreactive CT
Serum immunoreactive CT (iCT) levels in sex- and agematched control and tumor-bearing rats were measured by
radioimmunoassay using antisemm against human CT (17).
Testing of biological activity of the "'I-MoAb
A '^'I-labeled MoAb was tested by ELISA procedures for its
ability to bind CT in comparison with the binding ability of unlabeled MoAb. Human CT was pipetted into the 96 wells of a
polystyrene plate (Costar). The antigen was attached to the plate
by ovemight evaporation at 37°C. Before application of the primary antibody, the plate was treated with 1% bovine serum
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Fig 1—Comparison of binding of '^'I-labeled MoAb to calcitonin with that of unlabeled MoAb. as measured by ELISA
procedures.
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Fig 2—Tumor uptake ofI-labeled
one hour to 12 days.

MoAb over time course of

albumin solution to prevent nonspecific binding. MoAb, ' ^ ' I labeled and unlabeled, was added and incubated for one hour at
room temperature. After being washed with phosphate-buffered
saline (FBS)-Tween, the plate was incubated with rabbit antimouse peroxidase conjugate for one hour at room temperature.
After a final wash with PBS-Tween, peroxidase activity was
visualized with a substrate solution containing azino-diethylbenzthiazoline sulfonate and hydrogen peroxide. The color
intensity of the reactants was measured at 405 nm.
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fig 3—Uptake of '^'I-labeled MoAb by tumor on the sixth day
after injection as a function of dose of injected '^'I-labeled
MoAb.

In vivo uptake of "'I-labeled MoAb and "'I-labeled control
IgG by tumor and normal tissues
WAG/Rij rats bearing tumors of 2 to 3 g (three to four weeks
after transplantation) were used for localization experiments.
About 200 p,Ci of '^'I-labeled MoAb or ''T-labeled control IgG,
representing 25 to 40 p.g of protein, was injected intravenously
via the tail vein. The rats' thyroid glands were blocked by the
addition of sodium iodide to the animals' drinking water Wholebody scintigrams of the rats anesthetized with ketamine hydrochloride were taken with a scintillation camera one hour after
injection and every day for the next 12 days. Subsequentiy, day
six was selected for dissection of the animals and direct measurement of the radioactivity in the tumor and organs. The rats
were sacrificed by CO, asphyxiation. The tumors and various
organs were dissected, weighed, and counted for radioactivity
in a gamma counter (Nuclear Chicago, Model 4224). Blood was
withdrawn by cardiac puncture.
In some experiments in which blood distribution in the tumor
and organs was determined, this distribution was measured
using intravenous injection of "TnCl. In these experiments, a
group of tumor-bearing rats were subjected to similar experimental manipulations, except that they received no '^'I-labeled
MoAb or '3'1-labeled control IgG. The animals were injected
with 200 ixCi of '"InCl and were sacrificed 15 minutes later.
Blood was withdrawn and the organs were dissected, weighed,
and counted for '"In radioactivity.

Results
Serum concentration of immunoreactive CT in control and
tumor-bearing rats
WAG/Rij rats that received transplanted rMTC cells had a
semm iCT concentration of 4.0 ± 0.4 ng/mL at thetimeof the
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Fig 4—In vivo localization ofthe radiolabeled MoAb six days
after injection in tumors of differing weights.

Fig 5—Distributions of radiolabeled MoAb and control IgG in
tumor and normal tissues.

in vivo distribution experiments, whereas the age- and sexmatched control rats had a semm iCT concentration of 1.7 ± 0.6
ng/mL. The higher serum concentration of iCT indicated that
the transplanted tumors synthesized and secreted iCT in vivo.

Table
Uptake of Radiolabeled MoAb in Allografted MTC and
Normal Tissues in Rat Relative to Blood Concentration

Biological activity of the iodinated MoAb
The ability of the '^'I-labeled MoAb to bind human CT was
compared with that of unlabeled MoAb by the ELISA procedures. Fig 1 shows that the "'I-labeled MoAb bound CT in a
manner similar to that of the unlabeled MoAb, which suggested
that the iodination procedures did not affect the ability of the
MoAb to bind CT.

In vivo distribution studies
Fig 2 shows the ratio of "'I-labeled MoAb counts over the tumor compared with that over the abdomen during one hour to 12
days postlnjection. The uptake of the tumor increased gradually
after radiolabeled MoAb administration and reached a plateau
between the sixth and eighth days. We therefore selected the
sixth day postinjection as the time for studying the distribution
ofthe radiolabeled MoAb. Fig 3 shows the dose-uptake relationship of the '3'1-labeled MoAb in the tumor on the sixth
day after injection, A linear increase of uptake by the tumor
occurred between 6 and 38 p.g (40 and 250 p.g/kg), and localization of radiolabeled MoAb was proportionally related to
the weights of tumors when these ranged from 150 to 8,250 mg
(Fig 4). Consequently, no significant difference was seen in the
uptake of MoAb per unit weight of MTC when the tumors
were within this range of mass. We interpreted these results to
mean that the tumors examined for this study contained no
necrotic tissue.
On the sixth day after administration of radiolabeled MoAb,
we compared distribution of MoAb in the tumor and several visceral organs. A '^'I-labeled irrelevant mouse IgG was included
in these studies to serve as control for the nonspecific uptake of
" ' I in various tissues. Fig 5 summarizes the results. MTC tumors had an uptake of "'1-labeled MoAb of slightly more than
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i3iMabeled
MoAb (cpm/g)
3,12 X 10^
5,25 X 10'
1,89 X 105
1,22 X I0<'
1,41 X IO*1,98 X 10^
1,72 X 10"
3,79 X IO*

Organ
Blood
Mu.scle
Stomach
Spleen
Kidney
Liver
Lung
Tttmor

'"InCI
1,36
0,60
1,49
2,23
1,16
3,27
6,79
1,08

(cpm/g)
X 105
X 10^
X lO*
X 10*
X 105
X I0»
X IO*
X W

"•l/"iln Ratio*
1,00
3,82
0,55
2,.39
0,53
2,65
1,10
15,30

*Tissue/bIood ratio.

1,0% ofthe injected dose per gram of tumor, whereas the major
visceral organs had uptake values ranging from 0.05% to
0,54%. Distribution ratios of the radiolabeled MoAb were 1.2:1
for tumor-to-blood and 2-20:1 for tumor-to-organs. In the tumorbearing rats injected with the '^'I-labeled control IgG, the radioactivity distribution ratios were 0.4:1 for tumor-to-blood and
0.6-2:1 for tumor-to-organs.
Since vascularization and blood flow in tumors and organs
may differ, Gautvik et al (13) suggested that the difference in
blood volume of tumor and organs should be considered in evaluations of the affinity of antibody to its antigen in vivo. We
measured the blood distributions of the tumor and the organs
using intravenous injections of '"In. Uptake of '^'I-labeled
MoAb in the tumor and organs was expressed as the ratio of
'3'I/"'In, the blood ratio being set as equal to one. The data in the
Table, which lists the relative uptakes of radiolabeled MoAb in
tumor and organs in a typical experiment, demonstrate that
MTC tumor had an uptake ratio 15 times above that ofblood.

Discussion
CT is the most specific and sensitive marker of MTC (18). Our
study of the in vivo distribution of a MoAb against CT in MTCbearing rats showed that the MoAb localize in tbe tumor, and
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tiiat the tumor/blood ratio is about twotimeshigher than the ratio
of a polyclonal counterpart, as reported by Gautvik et al (13).
One would expect a high degree of variation in antibody distribution among different monoclonal or polyclonal preparations. Some Mo Abs may be capable of more effective tumor
localization than other preparations. Further studies comparing the activities of other antibody preparations against various
epitopes are required.
One striking difference in the results of our study and that of
Gautvik et al (13) concerned the radioiodination of the antibodies. The Gautvik group found that radioiodination, using the
chloramine-T method under conditions that were not specified,
resulted in products that did not bind antigens. In our study,
when the MoAb was iodinated by the chloramine-T method
using mild conditions, the labeled antibody bound to the antigen
in a manner similar to that of the unlabeled antibody, which indicated that the integrity of the antibody required for binding the
antigen survives iodination. We speculate that differences in the
nature of the proteins and in the conditions of iodination may
have contributed to the discrepancy.
The distribution of antibodies in vivo is undoubtedly related
to their binding characteristics, to blood supplies to the tumor
and organs, and to metabolic clearance ofthe antibodies. As the
Table shows, when ratios ofblood supplies to the tumor and major organs were considered together, the affinity of the MoAb for
the tumor seemed to be much higher than for blood or for normal
tissues. The nonspecific uptake by the visceral organs may represent the metabolic clearance of MoAb, the presence of crossreacting antigens in these organs, or microscopic metastasis
to these organs, although distant metastases were not apparent in the animals studied. One reason for the relatively low
proportion of MoAb localized to tumor (about 1% of injected
'^'l-labeled MoAb per gram) may be that CT is a secretory antigen that is constantly released into the blood stream. Whether or
not a MoAb against certain cell surface antigens of MTC would
localize more efficiently remains to be investigated.
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